Corrigendum to: Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis (Diabetes and Vascular Disease Research, (2018), 15, 1, (64-73), 10.1177/1479164117733626);Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis

Diabetes and Vascular Disease Research

Volumn 15, Issue 1, 2018, Pages 64-73

  Gaspari, Tracey ^a   Spizzo, Iressa ^a   Liu, HongBin ^a   Hu, Yunshan ^a   Simpson, Richard W ^a   Widdop, Robert E ^a   Dear, Anthony E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

atherogenesis; endothelial activation; Sodium glucose transporter type 2 inhibitor; vasoreactivity

Indexed keywords

APOLIPOPROTEIN E; DAPAGLIFLOZIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; ICAM1 PROTEIN, HUMAN; ICAM1 PROTEIN, MOUSE; SERPINE1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; VASCULAR ENDOTHELIAL CELL; VASODILATATION; ABDOMINAL AORTA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOLIPOPROTEIN E KNOCKOUT MOUSE; ATHEROSCLEROSIS; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; AORTA, ABDOMINAL; ATHEROSCLEROSIS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSIDES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT, APOE; NF-KAPPA B; PLASMINOGEN ACTIVATOR INHIBITOR 1; SODIUM-GLUCOSE TRANSPORTER 2; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION;

EID: 85038601912     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164118775894     Document Type: Erratum

References (19)

1. Monica Reddy RP, Inzucchi SE. SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 2016; 53: 364–372.
2. Zinman B, Wanner C, Lachin JM. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
3. Anderson SL, Marrs JC., Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012; 46: 590–598.
4. Terasaki M, Hiromura M, Mori Y. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One 2015; 10: e0143396.
5. −/− mice. Mediators Inflamm 2016; 2016: 6305735.
6. Ghosh RK, Bandyopadhyay D, Hajra A. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. Int J Cardiol 2016; 212: 29–36.
7. Katsiki N, Papanas N, Mikhailidis DP., Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19: 1581–1589.
8. Meng W, Ellsworth BA, Nirschl AA. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145–1149.
9. Vinh A, Widdop RE, Drummond GR. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 2008; 77: 178–187.
10. −/− mouse model. Diab Vasc Dis Res 2011; 8: 117–124.
11. Gaspari T, Welungoda I, Widdop RE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(−/−) mouse model. Diab Vasc Dis Res 2013; 10: 353–360.
12. Han Y, Cho YE, Ayon R. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol 2015; 309: L1027–L1036.
13. Shaw A, Doherty MK, Mutch NJ. Endothelial cell oxidative stress in diabetes: a key driver of cardiovascular complications? Biochem Soc Trans 2014: 42: 928–933.
14. Donato AJ, Morgan RG, Walker AE. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol 2015; 89: 122–135.
15. Hawley SA, Ford RJ, Smith BK. The Na+/glucose co-transporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 2016; 65: 2784–2794.
16. Schalkwijk CG, Stehouwer CDA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 2005; 109: 143–159.
17. Zhang L, Gong D, Li S. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 2012; 223: 78–85.
18. Libby P, Ridker PM, Maseri A., Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.
19. Shigiyama F, Kumashiro N, Miyagi M. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol 2017; 16: 84.